Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.
Target Price
The average target price of ELUT is 3.3 and suggests 199% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell